ClinicalTrials.Veeva

Menu

Treatment of Angiotensin Peptide (1-7) for COVID-19

K

Kanuni Sultan Suleyman Training and Research Hospital

Status

Completed

Conditions

COVID-19

Treatments

Biological: Biological/Vaccine: Angiotensin peptide (1-7) derived plasma

Study type

Interventional

Funder types

Other

Identifiers

NCT04375124
KSSEAH--0059

Details and patient eligibility

About

Novel Coronavirus is reported to cause COVID-19, recently. It's known that this virus uses ACE (angiotensin converting enzyme) 2 receptors to enter human cells and also blocks the activity of ACE 2. Upon these data the investigators hypothesize that, mortal hyper-inflammation state which is shown in COVID-19 cases, can be a result of angiotensin peptide (1-7) deficiency. Therefore, the aim of this study is to evaluate the possible effect of angiotensin peptide (1-7) supplementation on treatment of COVID-19 cases.

Full description

Novel Coronavirus is reported to cause COVID-19, recently. It's known that this virus uses ACE (angiotensin converting enzyme) 2 receptors to enter human cells and also blocks the activity of ACE 2. Upon these data the investigators hypothesize that, mortal hyper-inflammation state which is shown in COVID-19 cases, can be a result of angiotensin peptide (1-7) deficiency. Therefore, the aim of this study is to evaluate the possible effect of plasma derived angiotensin peptide (1-7) supplementation on treatment of COVID-19 cases.

Enrollment

9 patients

Sex

All

Ages

18+ years old

Volunteers

No Healthy Volunteers

Inclusion criteria

  • accepted to participate with an informed consent
  • proven positive COVID-19

Exclusion criteria

  • declined to participate
  • genetic/chromosomal abnormalities
  • any kind of history of previous adverse events with transfusion
  • diagnosis of immune deficiency

Trial design

Primary purpose

Treatment

Allocation

Non-Randomized

Interventional model

Parallel Assignment

Masking

None (Open label)

9 participants in 2 patient groups

non-peptide group
No Intervention group
Description:
This group will receive routine treatment and care for COVID-19.
peptide group
Active Comparator group
Description:
This group will receive angiotensin peptide (1-7) supplementation in addition to routine treatment and care for COVID-19.
Treatment:
Biological: Biological/Vaccine: Angiotensin peptide (1-7) derived plasma

Trial contacts and locations

1

Loading...

Data sourced from clinicaltrials.gov

Clinical trials

Find clinical trialsTrials by location
© Copyright 2024 Veeva Systems